Toyoaki Hida1, Vamsidhar Velcheti2, Karen L Reckamp3, Hiroshi Nokihara4, Pallavi Sachdev5, Tomoki Kubota6, Takuya Nakada6, Corina E Dutcus5, Min Ren5, Tomohide Tamura7. 1. Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. Electronic address: 107974@aichi-cc.jp. 2. New York University School of Medicine, New York, NY, USA. 3. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4. National Cancer Center Hospital, Tokyo, Japan. 5. Eisai Inc., Woodcliff Lake, NJ, USA. 6. Eisai Co., Ltd., Tokyo, Japan. 7. St. Luke's International Hospital, Tokyo, Japan.
Abstract
OBJECTIVES: Despite improved outcomes associated with immunotherapies for non-small cell lung cancer (NSCLC), many patients do not respond to treatment. Therefore, there is still an unmet need for molecularly targeted therapies in this patient population. Fusions of the RET oncogene have been identified as driver alterations in patients with NSCLC. Lenvatinib is a multityrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, RET, and other targets. This study evaluated the safety and efficacy of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. MATERIALS AND METHODS: In this phase 2, multicenter, open-label study (NCT01877083), patients with RET-positive lung adenocarcinoma received oral lenvatinib 24 mg/day. The primary end point was objective response rate (ORR) by investigator review per Response Evaluation Criteria In Solid Tumors v1.1 criteria. The secondary end points included safety and tolerability, progression-free survival (PFS), and overall survival (OS). RESULTS: Of 536 patients who screened for study inclusion and exclusion, 25 patients with RET translocations (KIF5B-RET [n = 13] and CCDC6-RET [n = 12]) were identified and received lenvatinib. The overall ORR was 16% (95% CI: 4.5%-36.1%). At data cutoff (February 3, 2016), the median PFS was 7.3 months (95% CI: 3.6-10.2) and the median OS was not reached. Duration of response was not estimable at the time of data cutoff. All patients experienced a treatment-emergent adverse event (TEAE); 23 (92%) patients experienced a TEAE of ≥ grade 3, and 6 (24%) patients discontinued lenvatinib due to a TEAE. The most common TEAEs were hypertension (68%), nausea (60%), decreased appetite (52%), diarrhea (52%), and proteinuria (48%). CONCLUSIONS: Lenvatinib demonstrated activity in patients with RET fusion-positive lung adenocarcinomas; although the response rate was relatively low, the median PFS supports the activity of lenvatinib in these patients.
OBJECTIVES: Despite improved outcomes associated with immunotherapies for non-small cell lung cancer (NSCLC), many patients do not respond to treatment. Therefore, there is still an unmet need for molecularly targeted therapies in this patient population. Fusions of the RET oncogene have been identified as driver alterations in patients with NSCLC. Lenvatinib is a multityrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, RET, and other targets. This study evaluated the safety and efficacy of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. MATERIALS AND METHODS: In this phase 2, multicenter, open-label study (NCT01877083), patients with RET-positive lung adenocarcinoma received oral lenvatinib 24 mg/day. The primary end point was objective response rate (ORR) by investigator review per Response Evaluation Criteria In Solid Tumors v1.1 criteria. The secondary end points included safety and tolerability, progression-free survival (PFS), and overall survival (OS). RESULTS: Of 536 patients who screened for study inclusion and exclusion, 25 patients with RET translocations (KIF5B-RET [n = 13] and CCDC6-RET [n = 12]) were identified and received lenvatinib. The overall ORR was 16% (95% CI: 4.5%-36.1%). At data cutoff (February 3, 2016), the median PFS was 7.3 months (95% CI: 3.6-10.2) and the median OS was not reached. Duration of response was not estimable at the time of data cutoff. All patients experienced a treatment-emergent adverse event (TEAE); 23 (92%) patients experienced a TEAE of ≥ grade 3, and 6 (24%) patients discontinued lenvatinib due to a TEAE. The most common TEAEs were hypertension (68%), nausea (60%), decreased appetite (52%), diarrhea (52%), and proteinuria (48%). CONCLUSIONS:Lenvatinib demonstrated activity in patients with RET fusion-positive lung adenocarcinomas; although the response rate was relatively low, the median PFS supports the activity of lenvatinib in these patients.
Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Alexander Drilon; Geoffrey R Oxnard; Daniel S W Tan; Herbert H F Loong; Melissa Johnson; Justin Gainor; Caroline E McCoach; Oliver Gautschi; Benjamin Besse; Byoung C Cho; Nir Peled; Jared Weiss; Yu-Jung Kim; Yuichiro Ohe; Makoto Nishio; Keunchil Park; Jyoti Patel; Takashi Seto; Tomohiro Sakamoto; Ezra Rosen; Manisha H Shah; Fabrice Barlesi; Philippe A Cassier; Lyudmila Bazhenova; Filippo De Braud; Elena Garralda; Vamsidhar Velcheti; Miyako Satouchi; Kadoaki Ohashi; Nathan A Pennell; Karen L Reckamp; Grace K Dy; Jürgen Wolf; Benjamin Solomon; Gerald Falchook; Kevin Ebata; Michele Nguyen; Binoj Nair; Edward Y Zhu; Luxi Yang; Xin Huang; Elizabeth Olek; S Michael Rothenberg; Koichi Goto; Vivek Subbiah Journal: N Engl J Med Date: 2020-08-27 Impact factor: 91.245
Authors: J J Lin; S V Liu; C E McCoach; V W Zhu; A C Tan; S Yoda; J Peterson; A Do; K Prutisto-Chang; I Dagogo-Jack; L V Sequist; L J Wirth; J K Lennerz; A N Hata; M Mino-Kenudson; V Nardi; S-H I Ou; D S-W Tan; J F Gainor Journal: Ann Oncol Date: 2020-09-29 Impact factor: 51.769